<DOC>
	<DOCNO>NCT00276783</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed disodium may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well pemetrexed disodium work treat patient recurrent malignant glioma , primary CNS lymphoma , brain metastasis .</brief_summary>
	<brief_title>Pemetrexed Disodium Treating Patients With Recurrent Malignant Gliomas , Primary CNS Lymphoma , Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 6-month progression-free survival rate patient recurrent malignant glioma treat pemetrexed disodium . - Determine time progression patient recurrent malignant glioma , primary CNS lymphoma ( PCNSL ) , brain metastasis treat pemetrexed disodium . Secondary - Determine radiographic response patient recurrent malignant glioma , PCNSL , brain metastasis treat pemetrexed disodium . - Determine time response patient treated drug . - Determine duration response patient treated drug . - Determine overall survival patient treated drug . - Collect safety data patient intracranial tumor treat drug . OUTLINE : Patients receive pemetrexed disodium IV 10 minute day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 47 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Malignant glioma , include follow subtypes : glioblastoma gliosarcoma , anaplastic astrocytoma , anaplastic oligodendroglioma , anaplastic mixed glioma , malignant glioma otherwise specify , meet follow criterion : Not require measurable evaluable disease Must fail prior radiation therapy &gt; 4 week ago Must fail least 1 prior chemotherapy regimen Confirmation tumor progression MR spectroscopy , PET scan , biopsy/resection prior radiosurgery perform Primary CNS lymphoma , meet follow criterion : Measurable disease define bidimensionally measurable lesion clearly define margin CT scan MRI Must fail least one prior chemotherapy regimen Must fail least one agent regimen Brain metastasis solid tumor , meet follow criterion : Measurable disease define bidimensionally measurable lesion clearly define margin CT scan MRI Biopsy require radiographic imaging consistent brain metastasis Must fail prior wholebrain radiotherapy Patients leptomeningeal metastasis without brain metastasis eligible therapy ( may diagnose MRI cytology ) Confirmation tumor progression MR spectroscopy , PET scan , biopsy/resection prior radiosurgery perform Effusions fluid collection must drain prior study entry PATIENT CHARACTERISTICS : Karnofsky performance score ≥ 60 WBC &gt; 3,000/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 10 mg/dL ( transfusion allow ) SGOT/SGPT &lt; 3.0 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN Creatinine &lt; 1.5 mg/dL Creatinine clearance &gt; 45 mL/min Women childbearing potential sexually active male must commit use effective contraception study 3 month complete study treatment Women pregnant breastfeeding eligible study treatment Negative pregnancy test Able take steroid , vitamin B12 , folate No significant medical illness infection , investigator 's opinion , adequately controlled appropriate therapy would compromise patient 's ability tolerate therapy Only one active tumor type allow , except nonmelanoma skin cancer carcinoma situ cervix A history malignancy acceptable complete remission therapy disease minimum 3 year PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior wholebrain radiotherapy Recovered side effect ( 6 week nitrosourea ; 4 week temozolomide , procarbazine , etoposide experimental agent ; 3 week isotretinoin tamoxifen ) ( patient gliomas ) No 2 prior chemotherapeutic agent regimen ( include biologic agent ) ( patient gliomas ) Recovered prior biopsy reresection tumor ( 1014 day resection 35 day biopsy ) ( patient gliomas ) May chemotherapy except hormonal therapy trastuzumab ( Herceptin® ) ( patient brain metastasis ) No limitation prior CNSdirected therapy ( patient brain metastasis ) Able discontinue nonsteroidal antiinflammatory drug ( NSAIDs ) Patients take NSAIDs aspirin require interrupt therapy least 2 day study treatment 2 day infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>primary central nervous system lymphoma</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult glioblastoma</keyword>
</DOC>